{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Baek MS"],"funding":["Soonchunhyang University","Korea Disease Control and Prevention Agency"],"pagination":["e353"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10593602"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["38(41)"],"pubmed_abstract":["<h4>Background</h4>There is insufficient data on the benefits of empiric antibiotic combinations for hospital-acquired pneumonia (HAP). We aimed to investigate whether empiric anti-pseudomonal combination therapy with fluoroquinolones decreases mortality in patients with HAP.<h4>Methods</h4>This multicenter, retrospective cohort study included adult patients admitted to 16 tertiary and general hospitals in Korea between January 1 and December 31, 2019. Patients with risk factors for combination therapy were divided into anti-pseudomonal non-carbapenem β-lactam monotherapy and fluoroquinolone combination therapy groups. Primary outcome was 30-day mortality. Propensity score matching (PSM) was used to reduce selection bias.<h4>Results</h4>In total, 631 patients with HAP were enrolled. Monoth"],"journal":["Journal of Korean medical science"],"pubmed_title":["Empiric Anti-Pseudomonal β-Lactam Monotherapy Versus Fluoroquinolone Combination Therapy in Patients With Hospital-Acquired Pneumonia: A Multicenter Cohort Study With Propensity Score Matching."],"pmcid":["PMC10593602"],"funding_grant_id":["2019-E2808-00"],"pubmed_authors":["Baek MS","Kim C","Lee HB","Cho WH","Hong SB","Park HK","Yoo KH","Jeon K","Baek AR","Chang Y","Korean HAP/VAP Study Group","Shin B","Min KH","Bae S","Gil HI","Moon JY","Lee HK","Kim JH","Oh JY"],"additional_accession":[]},"is_claimable":false,"name":"Empiric Anti-Pseudomonal β-Lactam Monotherapy Versus Fluoroquinolone Combination Therapy in Patients With Hospital-Acquired Pneumonia: A Multicenter Cohort Study With Propensity Score Matching.","description":"<h4>Background</h4>There is insufficient data on the benefits of empiric antibiotic combinations for hospital-acquired pneumonia (HAP). We aimed to investigate whether empiric anti-pseudomonal combination therapy with fluoroquinolones decreases mortality in patients with HAP.<h4>Methods</h4>This multicenter, retrospective cohort study included adult patients admitted to 16 tertiary and general hospitals in Korea between January 1 and December 31, 2019. Patients with risk factors for combination therapy were divided into anti-pseudomonal non-carbapenem β-lactam monotherapy and fluoroquinolone combination therapy groups. Primary outcome was 30-day mortality. Propensity score matching (PSM) was used to reduce selection bias.<h4>Results</h4>In total, 631 patients with HAP were enrolled. Monoth","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2026-06-02T19:00:43.429Z","creation":"2025-04-05T11:48:03.377Z"},"accession":"S-EPMC10593602","cross_references":{"pubmed":["37873633"],"doi":["10.3346/jkms.2023.38.e353"]}}